New responsibilities recognize Mr. Sardano’s significant accomplishments in securing CPT codes for office-based SRT and the growing commercial opportunity the Company now faces
Sensus Healthcare, Inc., a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological skin conditions, announced that President Michael Sardano has been appointed to the additional role of Chief Commercial Officer. In this newly created position, Mr. Sardano will direct the company’s global sales, marketing and commercial strategy across its portfolio of SRT technologies, Sentinel software and related service models.
Health Technology Insights: SOPHiA GENETICS, Element Bio Partner for AI Genomics
These expanded responsibilities follow a recent reimbursement milestone from the Centers for Medicare & Medicaid Services (CMS), which established current procedural terminology (CPT) codes specific to the use of superficial radiotherapy (SRT and IG-SRT) for non-melanoma skin cancer. This development has driven heightened interest and demand across dermatology and oncology practices. In his new role, Mr. Sardano will lead efforts to expand physician adoption of SRT, support recurring-revenue models and drive growth across U.S. and international markets.
“We believe we will see a notable uptick in interest for our technology, largely due to a more favorable reimbursement environment for our SRT product,” said Joe Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. “Michael has been at the forefront of securing these wins, while supporting commercial execution around this reimbursement milestone and the future ramp in demand. His strong leadership of our sales and marketing team, combined with our deep customer relationships and best-in-class SRT outcomes over 16 years, powerfully position us to capitalize on this next phase of growth with a heightened focus on commercial strategies.”
Health Technology Insights: EPI Expands Veteran Access to Anxiety and Pain Technology
“I’ve devoted my career to advocating the clinical and economic benefits of SRT, and I couldn’t be more excited about the latest momentum building around our technology,” said Michael Sardano. “With dedicated, clear, and favorable reimbursement now in place and an exciting new path for accelerated growth, we are redoubling our focus on expanding access to SRT nationwide and internationally so that more physicians and patients can benefit from this non-invasive, life-changing treatment. I look forward to working more closely with our outstanding commercial team to continue growing the company and advancing our mission.”
Michael Sardano joined Sensus Healthcare in 2010 to help start the company and joined full-time in 2013 as Corporate Counsel for Regulatory Affairs, and subsequently held leadership positions including Vice President & General Counsel and then President since 2022. He is a member of the Florida State Bar Association and holds a J.D. from New England Law and a B.S. in Management and Finance from Bentley University.
Health Technology Insights: Konovo Launches Survey Studio for Faster Survey Design
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
